Slides on Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies

Learn about the metabolic adaptations in obesity, the value of sustained weight loss, and the latest evidence for incretin-based therapies for long-term weight management.
Randy J. Seeley, PhD
Jenny Tong, MD, MPH
Kristina M. Utzschneider, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.07 MB
Released: March 17, 2021

Acknowledgements

Provided by Endocrine Society

For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.

In collaboration with Clinical Care Options
Supported by an educational grant from
Novo Nordisk Inc.

Related Content

Randy Seeley, PhD: Thoughts on body weight set points and how they affect obesity and its management from Clinical Care Options (CCO)

Randy J. Seeley, PhD Released: May 4, 2021

Jenny Tong, MD, MPH, answers questions about GLP-1 receptor agonists for weight loss treatment duration and weight stability and use in patients with obesity and related comorbidities

Jenny Tong, MD, MPH Released: May 4, 2021

Unlocked slides from Wing-Kin Syn, MBChB, PhD, FACP, FRCP and CCO: How to use biomarkers and imaging to evaluate NAFLD and NASH—ruling in or out hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Released: April 27, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue